Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Pre-clinical studies have shown that blocking activin type II receptors with bimagrumab leads to increased lean mass and decreased fat mass in mice
Prohibited in sport under the WADA Prohibited List, category S0 (Non-Approved Substances)
In a field moving this fast, dismissing these signals because no randomized controlled trial exists leaves patients without options they want and need now
Similar effects have been noted with DPP-4 inhibitors such as sitagliptin and vildagliptin, whereby supratherapeutic doses have succeeded in producing only a minor increase in the QT intervals [41, 42]
Additionally, it plays a role in reducing lipid peroxidation by decreasing levels of MDA (36)
June 13, 2025
